TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04619277

Intervention type: DEVICE
Intervention: drug-coated balloon
Description: drug-coated balloon

Intervention type: DEVICE
Intervention: drug-coated balloon
Description: drug-coated balloon

Intervention type: DEVICE
Intervention: drug-coated balloon
Description: drug-coated balloon

Intervention type: DEVICE
Intervention: drug-coated balloon
Description: drug-coated balloon

Intervention type: DEVICE
Intervention: drug-coated balloon
Description: drug-coated balloon
Study: NCT01048450

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Joint Resection- Keller Procedure
Description: These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
Study: NCT03447509

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iTMS
Description: Small magnetic pulse will be given to the brain in a non invasive manner.
Study: NCT01048450

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint Fusion
Description: Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemi-metallic Joint Implant
Description: Those who had a surgical procedure of a hemi-metallic joint implant
Study: NCT00896441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Citalopram
Description: Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.~Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.~Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.~Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.~Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.~Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI.
Study: NCT04140981

Intervention type: DEVICE
Intervention: ultrasounography
Description: in preoperative period, airway ultrasounagraphy for all patients will be made

Intervention type: DEVICE
Intervention: ultrasounography
Description: in preoperative period, airway ultrasounagraphy for all patients will be made

Intervention type: DEVICE
Intervention: ultrasounography
Description: in preoperative period, airway ultrasounagraphy for all patients will be made
Study: NCT01065779

Intervention type: DRUG
Intervention: FOSAMAX PLUS
Description: Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.

Intervention type: DRUG
Intervention: FOSAMAX PLUS D
Description: Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
Study: NCT04140981

Intervention type: DEVICE
Intervention: ultrasounography
Description: in preoperative period, airway ultrasounagraphy for all patients will be made
Study: NCT02476123

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)
Description: i.v. administration
Study: NCT02313883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PerioSept(r)
Description: Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PerioSept(r)
Description: Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PerioSept(r)
Description: Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IT, IV, or SC
Study: NCT02313883

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PerioSept(r)
Description: Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
Study: NCT00408005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV or PO
Study: NCT04317885

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prizloncabtagene Autoleucel
Description: Autologous 2nd generation CD19/CD20-directed CAR-T cells, single infusion intravenously
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV or PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given IV or PO
Study: NCT02380898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: 30 mg ketorolac immediately before induction of anesthesia

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 4 mL normal saline 0.9% immediately before induction of anesthesia
Study: NCT02393053

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Treatment with subepithelial connective tissue graft (SCTG)
Description: Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
Study: NCT03447509

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motor Task
Description: Participants will be asked to perform specific motor tasks or movements with their fingers, hands, and arms.
Study: NCT02393053

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Treatment with non-pedicled buccal fat pad graft (BFPG)
Description: Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
Study: NCT03698565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nerve stimulation of the ulnar nerve
Description: The intervention is the nerve stimulation of the ulnar nerve for evaluation / realization of PPI by videopupillometry.~The realization of PPI and ANI measurements is carried out at the end of the surgical procedure, it implies a maintenance of the anesthesia for approximately 5 additional minutes.
Study: NCT04151849

Intervention type: DRUG
Intervention: GLP-1 receptor agonist
Description: Treatment with GLP-1 agonist for up to 1 year.
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT04151849

Intervention type: DRUG
Intervention: SGLT2 inhibitor
Description: Treatment with SGLT2 inhibitor for up to 1 year
Study: NCT03639506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous mitochondria transplantation
Description: inject autologous mitochondria from bone marrow mesenchymal stem cells into oocyte

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)
Description: autologous mitochondria transplantation
Study: NCT00916656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrinogen Concentrate, Human (FCH)
Description: Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.~If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cryoprecipitate
Description: Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
Study: NCT03639506

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intracytoplasmic sperm injection (ICSI)
Description: intracytoplasmic sperm injection (ICSI)
Study: NCT04545047

Intervention type: BIOLOGICAL
Intervention: COVID-19 convalescent plasma
Description: Convalescent plasma collected from individuals who have recovered from COVID-19
Study: NCT02644941

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Acellular Vessel (HAV)
Description: Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ePTFE graft
Description: Surgical implantation of a commercially available ePTFE graft and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
Study: NCT03559959

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vouchers for HIV self-testing kits
Description: Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vouchers for HIV self-testing kits
Description: Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vouchers for HIV self-testing kits
Description: Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vouchers for HIV self-testing kits
Description: Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vouchers for HIV self-testing kits
Description: Participants will be given one referral voucher that offers a self-test kit at a randomly selected price point and distribution site. The vouchers will be valid for one month after the enrollment date. The other household members above 16 years of age will also be offered one voucher per person. Vouchers for the same household will have the same price, distributor, and promotion messages.
Study: NCT01000649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 202158 1.25
Description: FE 202158 at dose 1.25 ng/kg/min infused.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 202158 2.5
Description: FE 202158 at dose 2.5 ng/kg/min infused.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FE 202158 3.75
Description: FE 202158 at dose 3.75 ng/kg/min infused.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline infused.
Study: NCT01394835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha -1 Antitrypsin
Description: Inhalation twice daily of 160mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-1 Antitrypsin
Description: Inhalation twice daily .Dosage 160mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AAT
Description: Inhalation twice daily' 160mg
Study: NCT02387385

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body cooling (Tecotherm)
Description: Whole body cooling to 33 to 34 C using Tecotherm
Study: NCT00969007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification counselling
Description: Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
Study: NCT02516085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Study: NCT01892007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed RM - Online adaptive working memory training
Study: NCT03463395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reza band
Description: Reza band, a non-medication, non-surgical medical device designed to reduce symptoms of LPR has recently been approved by the FDA. It works by stopping the flow of gastric contents through the upper esophageal sphincter (UES) by increasing the internal pressure of the UES
Study: NCT00806923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: 80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
Study: NCT01892007

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cogmed RM - Online non-adaptive (placebo) working memory training
Study: NCT04153357

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: airtraq
Description: device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: c-mac
Description: device entering the oral cavity till visualization of the endotracheal tube entering the vocal cords
Study: NCT00806923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT00806923

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: 1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: iv on day 1 of each 3 week cycle until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 15mg/kg 1v on day 1 of each 3 week cycle until disease progression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
Study: NCT00131456

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: 375mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03281889

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam
Description: precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
Study: NCT03637712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer Algorithm
Description: This device is a computer algorithm that runs in the background during routine screening or surveillance colonoscopy that is designed to aid in the detection of polyps
Study: NCT00408005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT01341717

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin
Description: 100 mg once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 100 mg once daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: 1 mg/2 mg/3 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride
Description: 1 mg/2 mg/3 mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: \>=1000 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: \>=1000 mg twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: TDD \> 10 IU once/twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: TDD \> 10 IU once/twice daily
Study: NCT00408005

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin Calcium
Description: Given PO
Study: NCT02263911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally
Study: NCT01263015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir (also known as GSK1349572) 50 mg taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: Atripla once daily on an empty stomach

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abacavir/Lamivudine
Description: taken once daily; also known as EPZICOM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abacavir/Lamivudine Placebo
Description: matching placebo taken once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir placebo
Description: matching placebo taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atripla placebo
Description: matching placebo taken once daily on an empty stomach
Study: NCT03823846

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Dezocine injection
Description: Dezocine 10mg were intramuscular injected at 8:00am, 4:00pm and 12:00pm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjusted Dezocine injection
Description: Dezocine 10mg were intramuscular injected at at 6:00am, 2:00pm and 10:00pm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Dynastat or Flurbiprofen Axetil jinjection
Description: Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at 9:00am, 4:00pm and 12:00pm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjusted Dynastat or Flurbiprofen Axetil jinjection
Description: Dynastat 40mg or Flurbiprofen Axetil 50mg were administrated intravenously at at 6:00am, 2:00pm and 10:00pm.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postoperative rehabilitation
Description: Rehabilitation was conducted at 8:00am and 2:00pm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postoperative rehabilitation
Description: Rehabilitation was conducted at 8:00am and 2:00pm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal analgesia pump administration
Description: Dose of analgesia pump was added if needed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjusted analgesia pump administration
Description: Dose of analgesia pump was added if needed. Add one dose of analgesia pump 10 minutes before rehabilitation.
Study: NCT06546072

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: MRI

Intervention type: OTHER
Intervention: MRI
Study: NCT01345565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human hepatocytes
Description: The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.~We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant.
Study: NCT02127294

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcatheter patent foreman ovale closure